

# International Stem Cell

Strong biomedical sales and new clinical data

Pharma &amp; biotech

4 December 2018

**Price** **US\$1.57**  
**Market cap** **US\$11m**

Net debt (\$m) at 30 September 2018 0.9  
 Shares in issue 6.8m  
 Free float 41%  
 Code ISCO  
 Primary exchange OTC  
 Secondary exchange N/A

## Share price performance



International Stem Cell (ISCO) reported Q318 revenues of \$3.2m, up 73.0% compared to Q317 mainly due to the biomedical business, which had quarterly revenues of \$2.8m, up 112.8% year-on-year. Additionally, the company reported updated data from the Phase I trial of ISC-hpNSC in Parkinson's disease (PD). At the six-month time point, the percentage OFF-Time, a key endpoint for PD treatment, decreased an average of 49% for the second cohort of patients, compared to 24% for the first, with four patients in each cohort.

Year end	Revenue (\$m)	PBT* (\$m)	EPS* (\$)	DPS (\$)	P/E (x)	Yield (%)
12/16	7.2	(4.9)	(1.52)	0.0	N/A	N/A
12/17	7.5	(4.9)	(1.19)	0.0	N/A	N/A
12/18e	11.5	(3.2)	(0.50)	0.0	N/A	N/A
12/19e	13.5	(7.0)	(1.05)	0.0	N/A	N/A

Note: \*PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

## Commercial business continues to grow briskly

ISCO's commercial operations leverage its hpSC technology and generate revenues to partially offset R&D spending for therapeutic development. Lifeline Skin Care develops and sells skincare products and Lifeline Cell Technology produces human cell culture products for testing. Together they generated \$3.2m in sales in Q218, up 73.0% compared to the same quarter last year and provided \$0.8m in operating profit.

## Positive efficacy signals

The company presented updated data from its Phase I trial in PD at the Society for Neuroscience Annual Meeting on 3 November. Although data are still early and the sample is small (four patients per cohort), some positive efficacy signals were seen. Percentage OFF-Time improved by 49% in the second cohort compared to 24% in the first. Additionally, ON-Time without dyskinesia increased an average of 33% for the second cohort after six months compared to 19% for the first.

## Clean safety profile

So far, a total of 10 patients have received therapy in the trial. Importantly there have been no intra-operative complications and no serious adverse events associated with therapy. The most common adverse events include anxiety and headache.

## Valuation: \$42m or \$6.16 per basic share

We have adjusted our valuation from \$36m or \$5.72 per basic share to \$42m or \$6.16 per basic share. The increase in valuation is mainly due to higher revenue estimates for the biomedical business and rolling forward our NPV. We project that the company will need at least \$45m in additional financing before profitability in 2024 (down from \$60m due to higher revenues and continued cost controls), of which an additional \$8m will be required by the end of 2019.

## Business description

International Stem Cell is an early-stage biotechnology company developing therapeutic, biomedical and cosmeceutical applications for its proprietary stem form of pluripotent stem cells – human parthenogenetic stem cells. Its lead candidate is a cell therapy treatment for Parkinson's disease.

## Next events

Announce clinical development plan in PD 2019

## Analysts

Maxim Jacobs +1 646 653 7027  
 Briana Warschun +1 646 653 7031

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

[Edison profile page](#)

**International Stem Cell is a research client of Edison Investment Research Limited**

## Q318 results

The company reported Q318 revenues of \$3.2m, up 73.0% compared to Q317 (and up 5.2% sequentially compared to the previous quarter) mainly due to the biomedical business, which had quarterly revenues of \$2.8m, up 112.8% compared to the same quarter last year (and up 7.0% sequentially). The cosmetics business, however, was down 30.1% in the quarter and now represents just 11.3% of total revenues compared to 27.9% in the same quarter last year. The operating profit of the biomedical business also increased substantially, up 75.8% to \$1.0m, although the cosmetic business showed a loss for the quarter. The commercial businesses combined had a profit of \$768,000, up 133.4% compared to Q317. For the company as a whole, the operating loss was \$663,000 for Q318, a decline of 31.6% compared to last year. We have made some adjustments to our model, increasing our 2018 revenue estimate for the commercial business from \$11.2m to \$11.5m and our 2019 estimate from \$12.2m to \$13.5m due to higher than expected strength in the biomedical segment. We also decreased our SG&A expense estimate by \$0.3m in 2018 due to a lower than anticipated run rate.

### Exhibit 1: Changes to estimates

\$000s	Revenue			Operating profit			Profit after tax		
	Old	New	% change	Old	New	% change	Old	New	% change
2018e	11,165	11,459	2.6%	(3,508)	(3,057)	14.8%	(3,908)	(3,219)	21.4%
2019e	12,155	13,483	10.9%	(6,990)	(6,207)	11.2%	(8,190)	(7,009)	14.4%

Source: Edison Investment Research. Note: Operating profit and profit after tax exclude amortization of acquired intangibles, exceptional items and share-based payments.

The company had \$1.2m in cash on the balance sheet at the end of Q318. There was \$2.0m in a related-party payable stemming from a promissory note that provided cash to the company from its co-chairman and CEO, with the note due and payable on 1 November this year. Subsequent to the quarter end, the maturity date was extended to 15 January 2019. We project that the company will need at least \$45m in additional financing before profitability in 2024 (down from \$60m due to higher revenues and continued cost controls), of which an additional \$8m will be required by the end of 2019.

## Data presentation at the Society for Neuroscience

The company presented updated data from its Phase I trial in PD at the Society for Neuroscience Annual Meeting on 3 November. As a reminder, the trial is a dose-escalation study designed to evaluate the safety of the intracranial injection of 30m, 50m and 70m cells. The trial is also evaluating the treatment for efficacy by monitoring changes in brain function via PET scan, as well as functional assessment via various measures over 12 months.

With regards to the efficacy data, the percentage OFF-Time (percentage of the day when levodopa medication is not performing optimally and PD symptoms return) improved 49% in the second cohort compared to 24% in the first. Additionally, the percentage ON-Time without dyskinesia (percentage of day that medication is working optimally without dyskinesia) increased an average of 33% for the second cohort after six months compared to 19% for the first. Quality of life as measured by the Parkinson's Disease Quality of Life Score-39 Summary Index improved 47% for the second cohort and 15% for the first at the six month time point. Beck Depression Inventory (BDI) and Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease scores also improved with greater improvement for the higher dosed second cohort than the first.

One area of concern is in the 12-month follow up data for the first cohort as both the percentage OFF-Time and BDI rebounded from the six-month time point. This could be because the dose is too low as this is for the lowest dose cohort, it could also mean there might be a need for retreatment of

patients or it could simply be due to individual patient circumstances (which has the capability of moving the data markedly considering there were only four patients in the sample). Additionally, certain caveats apply to the data in general as this is a single-arm, open-label study, and no p-values were provided (although the trial was not powered to achieve statistical significance) making it difficult to draw any efficacy conclusions.

The safety profile of ISC-hpNSC continues to be clean. So far, a total of 10 patients have received therapy in the trial and there have been no intra-operative complications or serious adverse events associated with therapy. There is also no evidence of tumors, cysts, enhanced inflammation or infection. The most common adverse events include anxiety and headache.

## Valuation

We have adjusted our valuation from \$36m or \$5.72 per basic share to \$42m or \$6.16 per basic share. The increase in valuation is mainly due to higher revenue estimates for the base business and rolling forward our NPV.

Exhibit 2: International Stem Cell valuation							
Product	Status	Launch	Peak sales (\$m)	NPV (\$m)	Probability	rNPV (\$m)	NPV/share (\$/share)
Cosmetic and biomedical business	Commercial	Current	18	34	90%	34	5.00
Parkinson's disease (royalties at 12% of sales)	Phase I/IIa	2024	2,800	559	7.5%	42	6.19
G&A expense - after tax					100%	(33)	(4.91)
Net cash (Q318)				(0.9)	100%	(0.9)	(0.13)
Valuation				596		42	6.16
Source: Edison Investment Research							

**Exhibit 3: Financial summary**

	US\$000	2016	2017	2018e	2019e
Year end 31 December		GAAP	GAAP	GAAP	GAAP
<b>PROFIT &amp; LOSS</b>					
Revenue		7,165	7,456	11,459	13,483
Cost of Sales		(1,944)	(2,122)	(4,011)	(4,719)
Gross Profit		5,221	5,334	7,448	8,764
Research and development		(2,856)	(2,658)	(2,500)	(6,500)
EBITDA		(4,520)	(4,616)	(2,771)	(5,921)
Operating Profit (before amort. and except.)		(4,851)	(4,942)	(3,057)	(6,207)
Intangible Amortisation		0	0	0	0
Exceptionals		0	0	0	0
Other		3,772	(1,127)	1,137	0
Operating Profit		(1,079)	(6,069)	(1,920)	(6,207)
Net Interest		0	0	(162)	(802)
Profit Before Tax (norm)		(4,851)	(4,942)	(3,219)	(7,009)
Profit Before Tax (reported)		(1,079)	(6,069)	(2,082)	(7,009)
Tax		0	0	0	0
Profit After Tax (norm)		(4,851)	(4,942)	(3,219)	(7,009)
Profit After Tax (reported)		(1,079)	(6,069)	(2,082)	(7,009)
Average Number of Shares Outstanding (m)		3.2	4.2	6.4	6.7
EPS - normalised (\$)		(1.52)	(1.19)	(0.50)	(1.05)
EPS - normalised fully diluted (\$)		(0.34)	(1.46)	(0.32)	(1.05)
EPS - reported (\$)		(0.34)	(1.46)	(0.32)	(1.05)
Dividend per share (c)		0.0	0.0	0.0	0.0
Gross Margin (%)		72.9	71.5	65.0	65.0
EBITDA Margin (%)		N/A	N/A	N/A	N/A
Operating Margin (before GW and except.) (%)		N/A	N/A	N/A	N/A
<b>BALANCE SHEET</b>					
Fixed Assets		4,553	4,009	4,457	4,914
Intangible Assets		3,484	2,922	3,279	3,636
Tangible Assets		1,011	1,013	1,103	1,203
Investments		58	74	75	75
Current Assets		2,492	2,855	5,250	6,088
Stocks		1,390	1,307	1,682	2,407
Debtors		574	465	1,905	962
Cash		110	304	1,096	2,151
Other		418	779	567	567
Current Liabilities		(3,601)	(4,800)	(4,290)	(5,040)
Creditors		(3,601)	(4,800)	(4,290)	(5,040)
Short term borrowings		0	0	0	0
Long Term Liabilities		0	0	(2,025)	(10,025)
Long term borrowings		0	0	(2,025)	(10,025)
Other long term liabilities		0	0	0	0
Net Assets		3,444	2,064	3,392	(4,063)
<b>CASH FLOW</b>					
Operating Cash Flow		(4,197)	(2,142)	(1,010)	(3,400)
Net Interest		0	0	(162)	(802)
Tax		0	0	0	0
Capex		(944)	(864)	(706)	(743)
Acquisitions/disposals		0	0	0	0
Financing		4,018	3,200	645	(2,000)
Dividends		0	0	0	0
Net Cash Flow		(1,123)	194	(1,233)	(6,945)
Opening net debt/(cash)		(532)	(110)	(304)	929
HP finance leases initiated		0	0	0	0
Other		701	0	0	0
Closing net debt/(cash)		(110)	(304)	929	7,874

Source: International Stem Cell accounts, Edison Investment Research

---

#### General disclaimer and copyright

This report has been commissioned by International Stem Cell and prepared and issued by Edison, in consideration of a fee payable by International Stem Cell. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

**Accuracy of content:** All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the Edison analyst at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

**Exclusion of Liability:** To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out of or in connection with the access to, use of or reliance on any information contained on this note.

**No personalised advice:** The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

**Investment in securities mentioned:** Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

**Copyright:** Copyright 2018 Edison Investment Research Limited (Edison). All rights reserved FTSE International Limited ("FTSE") © FTSE 2018. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

---

#### Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd who holds an Australian Financial Services Licence (Number: 427484). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

---

#### New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

---

#### United Kingdom

Neither this document and associated email (together, the "Communication") constitutes or form part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. Any decision to purchase shares in the Company in the proposed placing should be made solely on the basis of the information to be contained in the admission document to be published in connection therewith.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document (nor will such persons be able to purchase shares in the placing).

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

---

#### United States

Neither this Communication nor any copy (physical or electronic) of it may be (i) taken or transmitted into the United States of America, (ii) distributed, directly or indirectly, in the United States of America or to any US person (within the meaning of regulations Regulation S made under the US Securities Act 1933, as amended), (iii) taken or transmitted into or distributed in Canada, Australia, the Republic of Ireland or the Republic of South Africa or to any resident thereof, except in compliance with applicable securities laws, (iv) taken or transmitted into or distributed in Japan or to any resident thereof for the purpose of solicitation or subscription or offer for sale of any securities or in the context where the distribution thereof may be construed as such solicitation or offer, or (v) taken or transmitted into any EEA state other than the United Kingdom. Any failure to comply with these restrictions may constitute a violation of the securities laws or the laws of any such jurisdiction. The distribution of this Communication in or into other jurisdictions may be restricted by law and the persons into whose possession this document comes should inform themselves about, and observe, any such restrictions.